Using the drop-down menu below, read about highlighted scientific news for patients from ASCO's Annual Meetings, Symposia, and medical journals for the past three years. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
The 2014 event was held May 30-June 3. The next ASCO Annual Meeting will be held May 29-June 2, 2015, in Chicago. To read the Annual Meeting summaries compiled into a yearly newsletter, you can also review Research Round Up: News for Patients from the ASCO Annual Meeting. Don’t forget to check out audio podcasts and videos about this news, as well. And a list of upcoming Symposia can be found here. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at different ASCO meetings. To search the entire collection of meeting abstracts, visit ASCO's website.
In a recent study, researchers found that the combination of olaparib and cediranib (Recentin) kept recurrent ovarian cancer from worsening for almost nine months longer than treatment with olaparib alone.
Results from a new study show that combining the targeted therapy ramucirumab (Cyramza) with standard chemotherapy lengthens the lives of patients with non-small cell lung cancer (NSCLC). Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.
According to new findings from a phase III clinical trial, women taking zoledronic acid (Zometa) for breast cancer that has spread to the bone, called metastases, can safely scale back to a once-every-three-months schedule after finishing a year of monthly treatments.
Early research suggests that lowering the dose of radiation therapy for some people with oropharyngeal cancer is an effective treatment option and may help reduce long-term side effects. This new approach customizes the radiation dose based on a person’s response to initial chemotherapy, as well as other factors known to affect a person’s chance of recovery, such as whether the tumor has tested positive for the human papillomavirus (HPV), the tumor’s size, and the person’s smoking history.
A new study demonstrates the benefits of a phone-based palliative care support program for caregivers of people with advanced cancer. The results suggest that the earlier palliative care services are introduced to caregivers, the better they will be able to cope with the caregiving experience.
According to new research, people who are expected to live less than a year can safely stop taking cholesterol-lowering drugs, known as statins, without shortening their lives. In fact, discontinuing statins provided a number of important benefits, including reducing symptoms, having to take fewer pills, and improving overall quality of life.
Results from a recent phase III clinical trial show that women who took goserelin (Zoladex) with chemotherapy for early-stage, hormone receptor-negative breast cancer were 64% less likely to develop premature ovarian failure, also called early menopause, compared with women who received chemotherapy alone.
According to a large study, men who have rising prostate-specific antigen (PSA) levels after surgery or radiation therapy may be able to safely hold off on receiving hormone therapy until they experience symptoms or other signs that the cancer has returned.
In a recent phase I clinical trial, about 50% of patients receiving a new targeted therapy for worsening non-small cell lung cancer (NSCLC) had the cancer shrink. Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. Specifically, this new targeted therapy, AZD9291, targets changes or mutations to the epidermal growth factor receptor (EGFR).
Early-stage research suggests that a new targeted drug, PLX3397, could become a treatment option for people with a neoplastic joint disorder called pigmented villonodular synovitis (PVNS). PVNS is a rare joint condition that usually affects the hip or knee, causing tumors to form in these joints that destroy joint tissue and cause severe, life-changing symptoms. PVNS is a type of uncontrollable cell growth, similar to a cancer, but it is not considered a cancer because it usually does not spread to other parts of the body.